8-KMaterial AgreementsFinancial Events

BIOGEN INC. 8-K Report, Material Agreement (Jun 16, 2005)

Filed June 16, 2005For Securities:BIIB

Summary

Biogen Idec Inc. (BIIB) announced on June 16, 2005, that it has entered into a definitive agreement to sell its large-scale biologics manufacturing facility in Oceanside, California, known as "NIMO," to Genentech, Inc. for approximately $408.1 million. This transaction is a significant strategic move that impacts Biogen's manufacturing footprint and employee base. The sale includes the real property, improvements, and related assets of the NIMO facility. A substantial portion of the approximately 430 employees at NIMO are expected to be offered employment with Genentech, with about 330 transitioning to the acquiring company. Biogen will retain the remaining employees and will provide transition services to Genentech post-closing. This divestiture may signal a shift in Biogen's operational strategy or capital allocation priorities. Investors should monitor the impact of this sale on Biogen's future manufacturing capabilities and financial performance.

Key Highlights

  • 1Biogen Idec to sell its NIMO biologics manufacturing facility in Oceanside, California, to Genentech.
  • 2The sale price for the facility and related assets is approximately $408.1 million.
  • 3Approximately 330 out of 430 NIMO employees are expected to be offered employment by Genentech.
  • 4Biogen will retain some employees at the facility and will provide transition services to Genentech.
  • 5The transaction is subject to closing conditions and is anticipated to close as early as June 23, 2005.
  • 6Biogen and Genentech have an existing collaboration on RITUXAN® (rituximab).

Frequently Asked Questions

This 8-K filing announces Biogen Idec's entry into a material definitive agreement to sell its NIMO manufacturing facility in Oceanside, California, to Genentech, Inc., and details the key terms of the transaction.

Biogen Idec will receive approximately $408.1 million from the sale of the NIMO facility. The filing also mentions that a portion of the purchase price will be used to complete certain construction work on the improvements at the facility, and Biogen will be reimbursed for costs related to employees transitioning to Genentech.

Out of approximately 430 employees at the NIMO facility, about 330 are expected to be offered employment by Genentech. The remaining employees are expected to remain with Biogen Idec.

Biogen Idec and Genentech are already collaborators on the development and commercialization of RITUXAN® (rituximab). This sale represents a significant asset transaction between these two established companies.